Schedin-Weiss and colleagues subsequently determined that alterations in CSF N-glycans correlated with the levels of phosphorylated tau and total tau in CSF, reinforcing the association between N-glycosylation, neurodegeneration, and tau pathology in AD[166]. The gene discussed is MAPT; the disease is Alzheimer disease.